[1] Jay F Mouser. New drugs for management of diabetes: insulin analogues, inhaled insulin, pramlintide, and novel peptides [J].Nutr Clin Pract, 2004, 19(2): 172-180.[2] Ilaria Dicembrini, Laura Pala, Carlo M Rotella. From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy [J]. Exp Diabetes Res, 2011, 2011: 898-913.[3] David G Parkes, Kenneth F Mace, Michael E Trautmann. Discovery and development of exenatide:the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1 [J]. Expert Opin Drug Discov, 2013, 8(2): 219-244.[4] Sunil Bhavsar, Sunder Mudaliar, Alan Cherrington. Evolution of exenatide as a diabetes therapeutic [J]. Curr Diabetes Rev, 2013, 9(2): 161-193.[5] David M Nathan, John B Buse, Mayer B Davidson, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy [J]. Diabetes Care, 2009, 32(1): 193-203.[6] Jae-Woo Kim, Kyutae Kim, Youjin Ahn, et al. Induction of insulin receptor substrate-2 expression by Fc fusion to exendin-4 overexpressed in E. coli: a potential long-acting glucagon-like peptide-1 mimetic[J]. BMB Rep, 2010, 43(2): 146-149.[7] 王俊红,郭永红,张静,等;重叠PCR 克隆Exendin-4 的基因及序列分析[J].中国医药导报,2013,10(15):13-15.[8] B Guerci, C Salaun Martin. Exenatide: its position in the treatment of type 2 diabetes [J]. Ann Endocrinol (Paris), 2008, 69(3): 201-209. [9] Ralph A Defrono, Curtis Triplitt, Yong-ming Qu, et al. Effects of Exenatide plus rosiglitazone on beta cell function and insulin sensitivity with Type 2 diabetes on metformin [J]. Diabetes Care, 2010, 33(5): 951-957.[10] Loretta L Niclsen, Andrew A Young, David G Parkes. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type2 diabetes [J]. Regul Pept, 2004, 117(2): 77-88.[11] 杨宇,吴江,杨欣,等. NT4一NAP融合基因原核表达载体的构建及在大肠杆菌的表达[J].中华神经内科杂志,2004,37(3): 260-261.[12] Loiler S A, Conlon T J, Song S, et al. Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver [J]. Gene Ther, 2003, 10(18): 1551-1558.[13] Anna Salvetti, Soizic Oreve, Gilliane Chadeuf. Factors influencing recombinant adeno-associated virus production [J]. Human gene therapy, 1998, 9(5): 695-706. |